Ocuphire to Participate in Upcoming Virtual HCW Conference in November
November 10 2020 - 10:09AM
Ocuphire Pharma, Inc., a clinical-stage ophthalmic
biopharmaceutical company focused on developing and commercializing
therapies for the treatment of several eye disorders, today
announced that will participate in the H.C. Wainwright 6th Annual
Israel Conference on November 12th, 2020.
H.C. Wainwright 6th Annual Israel Conference
– Thursday November 12,
2020 Presentation Time:
3:30pmWeblink:
https://journey.ct.events/view/9f6a3928-837c-4a93-9b61-8129988e8f9d
The Company recently announced the closing of a
previously announced private placement, and the completion of its
merger with Rexahn Pharmaceuticals, Inc. (NasdaqCM; REXN), and is
trading on Nasdaq Capital Market under the ticker symbol “OCUP”.
Ocuphire also recently hosted a KOL call with Key Opinion Leaders
Dr. Jay Pepose, M.D., Ph.D, Paul M. Karpecki, O.D., F.A.A.O., and
Peter Kaiser, M.D. covering the refractive and retinal
landscape. Webcast replay is available at
www.ocuphire.com.
About Ocuphire Pharma Ocuphire
is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic
biopharmaceutical company focused on developing and commercializing
therapies for the treatment of several eye disorders. Ocuphire’s
pipeline currently includes two small-molecule product candidates
targeting front and back of the eye indications. The company’s lead
product candidate, Nyxol® Eye Drops, is a once-daily
preservative-free eye drop formulation of phentolamine mesylate, a
non-selective alpha-1 and alpha-2 adrenergic antagonist designed to
reduce pupil size, and is being developed for several indications,
including dim light or night vision disturbances,
pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s
second product candidate, APX3330, is a twice-a-day oral tablet,
designed to inhibit angiogenesis and inflammation pathways relevant
to retinal and choroidal vascular diseases, such as diabetic
retinopathy and diabetic macular edema. As part of its strategy,
Ocuphire will continue to explore opportunities to acquire
additional ophthalmic assets and to seek strategic partners for
late stage development, regulatory preparation and
commercialization of drugs in key global markets. Please visit
www.clinicaltrials.gov to learn more about Ocuphire’s recent Phase
2 clinical trials. For more information, please visit
www.ocuphire.com.
Ocuphire Contact: Mina Sooch, President &
CEOOcuphire Pharma, Inc.(248) 681-9815
msooch@ocuphire.comwww.ocuphire.com
Rexahn Pharmaceuticals (NASDAQ:REXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rexahn Pharmaceuticals (NASDAQ:REXN)
Historical Stock Chart
From Apr 2023 to Apr 2024